CareTech.Human

Detection of diseases at the clinical stage often becomes too late. It leads to huge financial costs and deaths. That’s why preventive care is the world’s top strategic priority. However, preventive programs are often compromised with the human factor reported as one of the main causes. Patients skip preventive tests or don't have a habit to proceed meticulously.  That is the main challenge that we are committed to solve. 

CareTech.Human is an innovative point-of-care for fully automated health screening. Urinе contains biomarkers pointing to certain diseases. The innovation has sensors and unique pattern recognition technologies. When a person urinates, the device automatically collects air samples and transfers data to the cloud. AI/math algorithms process it and send an alert to the doctor if a marker was detected. 

Scaled globally, this will enforce a shift towards the preventive care model, increase health security and positively impact quality of life.

“7 out of 10 Americans die each year from chronic diseases, many of which are preventable"- according to CDC. The absence of screening habits is the main cause of failures in a battle with various diseases. Screening tests require human initiation, need to be scheduled in advance, and mostly are time consuming. It means that a lot of actions are needed from a person to collect relevant health data. Based on global statistics people only use preventive care at half the recommended cases. Failures of preventive care programs as well as ageing of the global population and increase of chronic diseases leads to excessive healthcare expenditures.  Healthcare budget optimization through preventive care is number one priority. $3.7 billion in medical costs could be saved annually in the US if preventive screenings are increased by 90%" - says U.S. Public Health Service.

Today,  the most popular products for home preventive care include test strips and semi-automated home point-of-care solutions. They offer a suitable accuracy level, however, all tests are human-initiated and as mentioned above it is the problem. To address this issue, our goal is to create affordable, accurate and fully automated POC, which will not require triggers from people.

We are creating fully automated, affordable, and accurate home point-of-care to detect biomarkers by analyzing the urine headspace. The screening tests are efficient when regularly taken for years. That’s why 100% automation is crucial to avoid behavioral factors. 

The product consists of hardware with innovative sensors operating for 3+ years without service and pattern recognition algorithm operating in the cloud and enabling required sensitivity and selectivity. 

The solution is designed to be installed in plug&play mode by the user wherever near the toilet. No special skills are required to start 24/7 preventive actions. Every time a person defecates, a gas probe is taken from the headspace through the silicon pipe placed inside the toilet bowl. The device analyzes the gas sample and sends data to the cloud. AI/math algorithms process the data and automatically send an alert to the doctor and user, if a marker was detected. The doctor makes the decision, whether further lab tests are required. Noteworthy, the data is gathered during each toilet visit, so that the dynamics and statistics could be additionally analyzed for the doctor’s decision making process. 

Vital early detection becomes affordable and won't require changes in human habit.

Target audiences and use cases were developed through conducting interviews, surveys, analyzing reports and working closely with doctors and patients’ organizations.

The first use case is regular and automated health checks, when device is in the place at home or in nursing homes, kindergartens, boarding schools. 

Audience - healthy people predisposed to certain diseases, such as diabetes, elderly population and those who are focused on continuous preventive health control. They are all searching for noninvasive, accurate and affordable ways to process screening on a regular basis to feel safe and detect illnesses at their earliest stage. 

The second use case is on-demand screening tests for public places like offices, restaurants or toilets. For instance companies all over the world are focused on increasing safety, comfort and productivity of their employees during the working period. When solution is placed in the office toilets, regular health checks are available. Each time a person wants to check their health status, they just need to scan the QR code by the app for identification and proceed to the screening test. Noteworthy, business application along with over-the-air technology of detecting algorithms, rapid health checks, can be quickly executed in case of disease outbreaks or epidemics.

The goal of the CareTech.Human startup is to create a fully automated POC to secure people's health invisibly, similarly to the fire alarm at your home. The solution will dramatically increase preventive care capabilities both for chronic diseases and new or rare illnesses for the communities all over the world. On the other hand, it will impact both individuals and public health organizations, providing a new generation of continuous, accurate, and online health data collection. GP doctors and other health workers will be able to use aggregate health data and automated insights for rapid data-driven decision making processes.

The key function of the product is detection of diseases at the earliest stage. Competitors include screening laboratory tests, home diagnostic devices and biosensors based solutions. 

Laboratory screening brands like Alere, ARKRAY, Bio-Rad, Mindray, Roche Diagnostics and Siemens dominate this market. Samples analyzed in a lab provide rather accurate results. However, they have a wide list of disadvantages, the biggest ones being high price and the need to visit a hospital. Although some of the companies declare the potential of applying their solutions as home point-of-care (POC), the main purpose is to increase laboratory performance.  

The main competitors in the home point-of-care segment are screening solutions based on biological sensors. Low price and simplicity are market advantages. However, their main disadvantage is human initiations and the need to substitute biosensor after each usage. Products designed for the analysis of urine using other sensing technologies are at different stages of R&D and are not commercially available. For instance, Japanese manufacturers of toilets Toto and Matsushita are widely known for taking several effective steps towards creating WiFi-connected toilets. However, these are also currently under development. 

The main innovations of the CareTech.Human product is the special sensing array, capable of withstanding 20,000+ measurements, accompanied by unique pattern recognition technologies, which enable over one thousand times higher sensitivity and selectivity. Developing complex algorithms while applying inexpensive sensors is promising in terms of designing truly affordable POC.

Diseases cause metabolic changes in the human body. So-called volatile organic compounds (VOC) are the end product of such disease-associated metabolism and can be excreted through breath, blood, urine, etc. 

VOCs are known to be highly potential biomarkers for disease detection due to sampling noninvasiveness and painless procedure. VOC sample analysis can be performed frequently to reflect disease progression and help significantly for continuous monitoring.  

The correlation between specific VOC sets have been proven for hundreds of disorders: diabetes, airway obstructions(asthma), respiratory infections(tuberculosis), cancer (lung cancer, prostate cancer, colorectal cancer), and other diseases. 

From the technology perspective, VOC biomarkers are typically detected using different variations of mass spectrometry (MS) analysis. MS-based methods can very accurately detect and identify VOCs, however, the measurements are time-consuming, expensive, and depend on a skilled operator, and also performed only in clinical settings. 

The recent game-changing novelty of new powerful analytical approaches and computing capacities, as well as breakthroughs in sensing technologies, has enabled the detection of low concentrations of VOC biomarkers using other technology called eNose. The eNose is an instrument that comprises an array of sensors accompanied by pattern recognition algorithms. eNose has a very strong potential to overcome MS methods disadvantages mentioned above. Point-of-care based on eNose technology could be cheap, automated, and accurate enough for early detection or screening purposes. 

The CareTech.Human team used eNose principles, significantly developed (advanced) sensing arrays and math algorithms and accomplished them with AI and machine learning technologies.

The diagnostic potential of odors and aromas was first utilized by ancient Greek physicians[1,2]. During the last 25 years, a significant amount of VOC released via urine, saliva, and breath were proven to be related to specific diseases[1,2,3,4,5]. Generally, VOC detection was proven to be a non-invasive and efficient diagnostic method. 

However, the main blocker of wide adoption has been complexity. Gas chromatography-mass spectrometry (GC-MS), mass spectrometry (SIFT-MS), proton-transfer-reaction mass-spectrometry are considered the “gold standard” for VOC analysis [1,2,3]. Although these methods are highly reproducible and accurate, yet they are time-consuming, expensive, and depend on a skilled operator which makes them impractical to be applied widely in outside clinical settings.

Over the last 5 years, the significant breakthrough in sensing and AI technologies enabled the high potential of eNose to overcome these disadvantages[1,2]. eNose technologies are relatively inexpensive, easy to use and provide a rapid analysis. As proof of eNose technology readiness level various devices in other industries can be analyzed[1,2,3,4,5]. 

The majority of reviewed studies in medical applications show promising results, often surpassing the accuracy and sensitivity of established diagnostic methods[1]. It is reported that the eNose technology was successfully applied for airway obstructions, respiratory infections, inflammatory diseases, cancer, and other diseases[1,2]. Along with various scientific papers mentioned above, eNose technology is reported to be applied in health devices prototypes to some extent similar to CareTech.Human products[1].

The problem range was described in full in the previous chapters. Here is the impact and 3 main beneficiaries that are affected by CareTech.Human solution. (Supporting diagram).

Healthy population. With CareTech.Human solution people can have automated regular screening tests, which in turn are analyzed by AI resources. Results are automatically delivered to medical staff for review. These activities will allow people to receive automated health feedback and recommendations. In the near future, this will strengthen the change of the healthcare system towards continuous health monitoring and the ability to track individual parameters. As a midterm outcome, those factors will continue to support the digitalization of all health records and enable personalized approaches to food selection, medication and lifestyle. In the long run, high-quality care will be achieved by introducing predictive and personalised medicine.  The ultimate impact is to improve key health indicators: life expectancy and healthcare index.

Individuals who are in the risk zone or predisposed to some disease. Continuous health data collection and analysis will enable capturing the smallest deviation in metabolism or detect biomarkers and send notifications to undergo focused detailed diagnostics. Early disease detection in turn will allow substantial improvement in medical therapy response and faster recovery. These should empower the increased percentage of prevented and treated disease, as a result, improve morbidity indicators and save more lives.

Government. By providing affordable instruments to reveal diseases at an early stage  the quality of the healthcare system will be improved. It’s anticipated that immediate expenses on medications and hospitalization will be reduced and funds can be relocated to other life-saving programs. Consequently, the vision is that CareTech.Human solution will optimize healthcare expenditures not only at the personal but also at the national level.

24/7 monitoring leads to continuous health data collection. Big data analysis will enable the Government and other authorized parties to receive a helicopter view and high-level healthcare insights. Among other big data values having this information in place makes early pandemic detection possible and allows to build data-driven healthcare strategies. These two elements will improve global health security.

The project has passed the proof-of-concept stage. A series of lab prototypes were created and iteratively tested and adjusted. The technologies of sampling, data processing, data transfer to the cloud have been successively developed. Mathematical models, machine learning technologies were developed and verified. The unique sensing arrays were developed and tested. Required device sensitivity of 1-50 ppm was tested by a certified metrology organization. Laboratory testing demonstrated the viability of the concept.

The startup is currently at the pre-revenue stage and there are no users, however, the strategy for the next 7 years was created. CareTech.Human is planning to launch four versions of the product.

Well-being device capable of detecting metabolic changes and providing wellness-related advice and feedback will be piloted in 2022 and launched commercially in 2023. It will be distributed as a home POC as well as on-demand POC for public places. 

The POC to detect markers of the earliest stages of diseases. At the moment, the team is focused on diabetes and gastroenterological diseases, as well as products for TB medicine intake control. Both streams will pass through regulatory clearance and will be launched in 2024.

By the end of 2024, the client base for all solution’s use cases will be around 200,000 people. In five years we plan to distribute at least 300,000 devices among households, nursing homes, and kindergartens. It will directly serve more than 5 million people and will overall impact 10 million including relatives and family members.

First category is the created values for strategic goals and global challenges. The team will influence healthcare system transformation towards preventive care model by providing new screening facilities. Second category consists of the made values for the healthcare system, such as improving consistency of data, improving patient/doctor interaction, data driven diagnosis and treatment. For instance the solution scans urine during each urination. Thus the data is regularly obtained providing insights to GP doctors and enabling data driven and accurate diagnosis.  The last but not least is the values that are created for patients/people. By controlling the urine markers and receiving continuous feedback people can prevent diseases, control their nutrition and physical activity level and as a result influence their productivity, health and quality of life. 

To achieve this goal, within the next five years the team is going to roll out several products based on the core solution. 

First are well-being devices installed both in living and public/working places. They will serve as a metabolism feedback tool providing important feedback and insights. Along with improving the AI/ML algorithm on received data and moving further with regulatory clearance, the solution will be continuously increasing the number of analyzed biomarkers.  

On the other hand the product for detection of dangerous diseases like diabetes as well as  for controlling pregnancy and kids metabolic deviations was prototyped. It is planned to be delivered to the market in 2024.

Deloitte's research demonstrates that only 86 out of 895 healthcare startups that were founded between 2010-2019, managed to survive and deliver added value to the market and people. Aiming to avoid pitfalls and obtain knowledge, the Project team analyzed 56 case studies, 26 analytical reports, and 105 whitepapers. 

The first point in the risk profile is creating the right product-market fit. The global trend on the value-based approach sets strict requirements towards health-care products and their matches with client’s needs and business processes.

Second is the regulatory frameworks are known to be extremely strict. Various delays during regulatory processes can stretch the budget, increase time to market, and lead to bankruptcy.

The next significant challenge for IoT solutions is cybersecurity. Multiple studies showed that health data are one of the most sensitive. Mistakes in manufacturing, infrastructure design, cyberattacks protection and business processes design can kill the startup. In the next five years we will have to solve interoperability and interconnection issues. Privacy and security challenges associated with the exchange of health information along with the absence of a single standard for electronic health records systems. 

Needless to say, there are funding risks. It is no surprise that innovative medical device development has a wide range of uncertainties.  Stepbacks and delays can be caused by development, regulatory, market, and other issues. On top of that, the project needs enough capital to cover the idle period between the time the product is ready de facto and when FDA clearance is received.

1. Risk of the right product-market fit. To overcome this challenge the relationships with patient organizations, sales partners, potential distributors, insurance companies, experienced individual consultancies were established. The product and market hypotheses were consciously verified. The approach will be strengthened with client segments test campaigns, pilot projects, focus group tests etc.

2. Regulatory clearance. As first step, collaboration with a regulatory consultancy with a proven track record has been planned and budgeted. As soon as clinical units are ready the team will start negotiating with FDA to hear the concerns and feedback. On the other hand, clinical units will be piloted in the research environment, rather than applied in clinical practice directly after regulatory approval. By conducting pilots with different facilities the Project team will also establish relationships for further business development and sales activities. 

3. Cybersecurity. To avoid mistakes, we established a partnership with GlobalLogic. The global IT company is highly experienced in life-critical medical devices development. Furthermore, the startup roadmap includes pre-releases security and penetration tests. 

4. Interoperability and interconnection issues are also capable of catching the medical innovation off guard. We are designing business models based on interaction with telehealth, medical/laboratory/patient information systems and POCs. A wide range of secure, HIPAA and GDPR compliant APIs is planned to be developed.

5. Fundraising. The first is to diversify funding sources. The second is to have at least one year of the budget allocated. The third is to negotiate contracts, make sales, and get pre-orders from potential partners to potentially enable overdrafts and credits.

The project team is gender-balanced and consists of onshore and offshore squads. Each participant has a unique competence profile and background for the successful project implementation. 8 key team members are involved on a full-time basis working with embedded technologies, AI, BD, IoT, fundraising and IP.  

Partner organisations (Global Logic, CO 100%Life, Ilmenau University of Technology) provide 6 highly-skilled specialists who are taking care of several streams (data security, bulk production etc) where specific domain knowledge is needed.

To verify market approach, strategy, technology and tactical decisions 3 well-respected scientists were invited to join the advisory board.

A balanced team is vital to creating an innovative startup. From the very beginning competence analysis was performed and the talents engaging process was launched. As a result the gender balanced (9 men, 8 women) highly motivated team was gathered and has already been working  for more than one year. Half of the team members have relevant PhD degrees.

The founder - Dan Matsui is in charge of the general management, product, market approach, vision and business development. He has unique combination of scientific (PhD in Physics, developed novel sensing material), entrepreneurial (3 successful exits) and healthcare (as a CEO of SOE eHealth led the global digital transformation of Ukrainian primary healthcare sector)  backgrounds.  

The product development team has a proven track record of developing successful IoT, AI/ML sophisticated IT systems when working in global corporations and tech firms. The solid experience of the internal squad is heavily supported by the dedicated team of 6 embedded engineers provided by the partner. This part of the team has created several medical devices which passed regulatory clearance. 

The IP, fundraising and regulatory tasks are significant. People responsible for this area despite sitting on a huge portfolio of successful cases are experienced mainly in healthcare. It is hard to overestimate domain experience. 

To mitigate other risks and to bring additional expertise in market and technology the advisory board was founded. Now 3 outstanding scientists from Ukraine and Germany help cope with medicine, biochemistry, technical issues as well as international communications and partner involvement.

In order to reach the above mentioned goals , CareTech.Human partners with organizations to support product, market and fundraising tasks.

• GlobalLogic is an international IT company. It combines deep domain expertise with cross-industry multiskills and is especially highly experienced in life-critical medical devices development. It contributes to the startup with unique experience and diverse engineering expertise. The agile and lean processes set between the onshore team of GL’s 6 dedicated senior engineers enable short product development sprints and quick hypothesis tests. 

• CO “100% Life” is the largest patient-led organization in Ukraine. It has a proven record of managing funds of large-scale grants from different donors - among them: the Global Fund, USAID, French Initiative 5%, UNFPA, UNITAID, embassies of numerous countries. The Global Fund assigned A1 rating to “100%Life”, which is the highest rating among organizations and strongly evaluates programs activities and outcomes. In 2016, the organization received PEPFAR award for best partnership among patients' organizations from 40 countries. For CareTech.Human CO “100% Life” is a reliable partner in mitigating risks of targeting wrong market needs. They share knowledge about healthcare industry stakeholders needs, best practice, networking and international communications. 

• The Technical University of Ilmenau is among top German public universities. It has over 100 years of research and education history. It brings the project strong expertise in AI, novel sensing technologies, R&D facilities and market connections. 

• Ukrainian Startup Fund is a country-wide investment program that funds the most talented Ukrainian entrepreneurs. It provides grant support to the projects.

The customers’ segments were described while answering “Who does your solution serve”. In a nutshell, these are people predisposed to certain diseases or aiming to control their health level. Serving these customer groups other stakeholders also benefit.

Added values of the product could be divided into three categories:

1. The created values for strategic goals and global challenges. Epidemics, disease outbreaks, healthcare costs optimization, healthcare system transformation etc. 

2. The made values for the healthcare system - improving consistency of data, improving patient/doctor interaction, data driven diagnosis, etc. 

3. Third category is the values that are created for patients/people. 

The potential customers are insurance companies, healthcare organisations, corporate and end users. 

The relations with organizations are focused on long-term win-win cooperation, maximum personalized as well as co-creative. While developing their knowledge about the technology, team expects to gain insights and customize products based on the regional or other needs. 

The end user relations are going to be fully automated with continuous client education regarding the preventive care opportunities and product functions. 

The pricing model will consist of device cost and several available subscription plans. It will vary on the use case and product variation. Also third parties integrated with the solution to get data or insights will be charged based on the subscription or pay-as-you-go model.  

The estimated cost of production (BOM&COGS) is between $65-95. The retail pricing strategy as well as price elasticity of demand requires additional studies. At the moment the financial model includes an averaged price $650.

2019 and 2020 are product prototype R&D years. Founders, grants, and volunteers are the main sources of funds and resources. Annual burning rates for 2019-2020 are 105,000US$ and 185,000US$ respectively.  

In 2021, the team's goal is to create a clinical unit for pilot trials, experimental clinical runs and FDA regulatory class 1 clearance in 2022. Annual burning rates for 2021 and 2022 are 720,000US$ and 2,100,000US$ respectively. Several sources of funds for this period are expected. Late seed VC round (2,000,000US$), grants (700,000US$) and income from corporate sales and preorders (500,000US$). 

In 2023 the team aims to facilitate sales of the wellbeing solution within individual and corporate segments. It will be capable of detecting general changes in metabolism and providing users with feedback on dietary, physical activity and other important wellness related information. Also the medical version of the product will deal with FDA class 2 regulatory clearance. To pass FDA clearance and significantly boost sales within the preventive POC solution segment, additional funds will be needed. In 2024 Round A will be raised. Approximately 8,000,000US$ will be acquired with startup evaluation around 30,000,000US$. 

In 2024 the CareTech.Human goal is to have 22 000,000US$ income which is broken down as follows - well-being products (8,500,000US$), preventive care medical POC distributions (7,000,000US$), and preorders for the following year (6,500,000US$). It will fully cover expected expenses and enable further growth.

By taking part in the Solve’s programs the Caretech.Human hopes to strengthen competencies and mitigate risks, especially in business development and product  areas. Startups can overcome the mentioned barriers by getting unique knowledge, insights about  market needs, specific internal business processes and decision making patterns. 

The MIT Solve partners connected with the healthcare industry and presented on the website were analyzed and considered as very important for startup development. By joining the MIT Solve, Caretech.Human is expecting to gain extra expertise while interacting with health oriented funds, private medical organisations, public healthcare organizations and research institutions. 

Great hopes are placed on negotiations with leading corporations to conduct pilot projects and to quickly receive market validation of the product itself and particular features.  

Mentors. The team requires mentorship and strategic advisors in all areas of business development globally and on the US market specifically. To avoid pitfalls with the commercialization of products the team is expecting to be navigated by experienced MIT peers.  

There are expectations to win prizes as Caretech.Human solution, which fully fits the priorities of the Elevate and AI for Humanity Prizes. These funds can significantly boost R&D facilities and the product development process. Entering Solver Movement can bring the desired exposure of solution to a wider audience and speed up the path toward the global changes and impact.

Caretech.Human sees joining the MIT community as an entry point to the source of best practices, knowledge, and holistic support in the decision making process.

Collaboration between technology start-ups and large corporations is crucial for success. This strategic partnership can support start-ups to create their project and corporations to enter and make new markets. 

1. Main risks mitigation. Main risks were described above. To mitigate them experienced partners and advisers are needed in order to provide domain knowledge, expertise and professional service. In particular research institutions, IT firms, patient organizations, research institutions etc.    

2. Business development. To conduct pilots, adjust the business model, customize the product for specific use cases, the team lacks partners from insurance, pharmaceutical, telemedicine and diagnostic industries. 

3. Outsource non prevalent functions. Aiming to achieve goals of quick growth and in parallel to pay attention to the smallest details, the team is searching for partners to take care about volume-based manufacturing and quality control, logistics and legal tasks.

4. Fundraising. To execute it accurately the team is looking for relevant networking and fundraising consultants.

Taking into consideration the team’s strategic partnership roadmap, at the current stage we are looking for:

1. Insurance companies that are interested in minimizing payments through prevention, as well as expanding their product portfolio.

2. Healthcare companies that are focused on implementing medical and wellness solutions.

3. Telemedicine services strengthened by IoT/ point-of-care products and of course government programs aimed to increase preventive actions.  

4. Public Healthcare Organizations to discuss their strategies and how our approach  corresponds. 

We have extensively studied the organizations, the MIT faculty, the initiatives and Solve Members. This is a list of very worthy, well-known, reliable organizations with whom we would like to partner. Among those we could partner with to strengthen our project with their expertise (as an example) are Bill & Melinda Gates Foundation, Vodafone Americas Foundation, MetLife, Firefly Innovations at CUNY Graduate School of Public Health and Health Policy, Americares.

What would happen if people could detect diseases at their earliest stages? Years or months before any symptoms occur. At a point, when all you need is to take the smallest amount of medicine to stop illness.

What would happen if people were able to monitor their key health indicators continuously without any involvement to understand how their diet, habits or work life balance are influencing them? 

The potential is overwhelming!

From a rational perspective, the Caretech.Human solution is about healthcare security. However, from the emotional side, it’s about  confidence in the future, peace of mind for yourself and your loved ones. Caretech.Human is about care, safety, reliability and efficiency and about avoiding health related bankruptcies.

Caretech.Human creates a powerful tool to satisfy basic people's desire to be safe  but at a level that had never before been available outside the laboratory. The team is bringing analysis that exists only in the lab to every household even in the least developed countries. By making it truly affordable, solution enables people who earn less than 5US$ per day to experience the same level of health security as the ones that live in developed economies. The team believes that by combining powerful diagnostic sensing technology, artificial intelligence, math algorithms and by utilizing novel cloud computing capacities, it is possible to drive enormous breakthroughs in the global healthcare industry.

The Elevate Prize for Health Security will help the Caretech.Human team implement a number of R&D streams, deliver life-changing value to humanity exponentially faster!

This is not a world that is emerging, it is a world we are creating. Nowadays there are many areas of human activities where artificial intelligence, machine learning and big data are used and have colossal importance.

However the healthcare industry sits at the forefront of this effort. The modern medical devices facilitate the exponential growth and availability of biomedical data. On the one hand it creates new opportunities for data driven decision making processes, early prevention and healthcare security. It is, however, also challenging because millions of parameters simply cannot be processed by humans. The AI has the most direct use and creates a significant difference in the quality of people's care.

CareTech is using the “odor sniffing” principle that even ancient Romes tried to apply with the help of the dogs. This technology was abandoned for centuries because there was no possibility to develop it in a scalable and applicable way. The dramatic development of AI technologies fueled it. Now Caretech.Human is using high-tech algorithms for odor pattern recognition. Along with cloud computing capacities it enables the technology to deliver outstanding results that have never been available before.  The AI is a soul of the CareTech.Human solution aimed to benefit humanity. 

Thanks to The AI for Humanity Prize Caretech.Human will be able to create expensive gas mixtures to gather rare and unique referral data sets. This will make it possible to move further with the detection of patterns of some dangerous diseases. Along with that it will be able to strengthen the product steam that is committed to develop the urine fingerprint technology to automatically distinguish family members by unique metabolic signatures. 

With the AI for Humanity Prize, Caretech.Human will not only increase global health security, but also influence the change in societies across the globe to use artificial intelligence for social good.